Outcomes of Subthreshold Laser Versus Intravitreal Injection of Ranibizumab in Diabetic Macular Edema

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-12-31

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is To compare the anatomical and functional results of intravitreal( IV) injection of ranibizumab with sub threshold micropulse laser ( SML) in treatment of Diabetic macular edema (DME) both anatomically by spectral domain optical coherence tomography (SD OCT) and functionally by best-corrected visual acuity (BCVA) and multifocal electroretinogram (mfERG).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Combination of Intravitreal Ranibizumab With or Without Micropulse Laser for the Treatment of DME

NCT03690947

Diabetic Macular Edema

COMPLETED PHASE4

Safety and Efficacy of Ranibizumab in Diabetic Macular Edema

NCT01131585

Visual Impairment Due to Diabetic Macular Edema

TERMINATED PHASE3

A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema

NCT06305416

Diabetic Macular Edema Diabetic Retinopathy Macular Edema +3 more

RECRUITING PHASE3

Effect of the Vitreous in Response to Intravitreal Injections of Ranibizumab for the Treatment of Diabetic Macular Edema

NCT04387604

Diabetic Macular Edema

COMPLETED

Subfoveal Choroidal Thickness and Visual Acuity After Intravitreal Injection of Ranibizumab in Diabetic Retinopathy

NCT06173245

Subfoveal Choroidal Thickness Intravitreal Ranibizumab +2 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Diabetic macular edema (DME) causes significant visual loss in diabetic patients. About 20% and 40% of patients with Type 1 and Type 2 diabetes mellitus (DM), respectively, develop DME. One-third of diabetic patients who have had DM for more than twenty years will develop DME . Early impairment in the function of the middle and inner layers of the retina has been reported in diabetic patients before appearance of vascular complications . A good independent guide of macular function in patients with DME is multifocal electroretinogram (mfERG) readings from the macular area, which strongly associate with morphologic alterations in the macula. Some investigators suggested that temporal characteristic (implicit time) of mfERG waves are more important than amplitudes for evaluation of retinal function in diabetic patients. They concluded that patients with DM show temporal changes indicating delayed neural transmission due to local impairment of blood glucose metabolism. In contrast, others emphasize the importance of both parameters (implicit time and amplitude) in identifying retinal affection in DM.

Intravitreal (IV) injections of anti-vascular endothelial growth factor (VEGF) agents provided good visual outcomes in treatment of DME. However, IV anti-VEGF injections are expensive, need to be repeated many times and have the potential risk of causing endophthalmitis . Subthreshold micropulse laser (SML) treatment of DME has the same effect as conventional laser treatment, nonetheless, there is less damage to adjacent tissues of the burn area in the retinal pigment epithelium (RPE). SML allows laser emission to be divided into bursts of short cyclic pulses that remain for microseconds permitting substantial cooling amid these short pulses .

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Macular Edema

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

group 1

group 1 of DME which treated by SML

Group Type ACTIVE_COMPARATOR

laser interference,INTRAVITREAL INJECTION

Intervention Type PROCEDURE

sub threshold micro pulse laser for DME for group 1 and intravitreal injection of Ranibizumab for group 2

group 2

Group 2 of DME which treated by intravitreal injection of Ranibizumab

Group Type ACTIVE_COMPARATOR

laser interference,INTRAVITREAL INJECTION

Intervention Type PROCEDURE

sub threshold micro pulse laser for DME for group 1 and intravitreal injection of Ranibizumab for group 2

group 3

control group of diabetic patients received no treatment

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

laser interference,INTRAVITREAL INJECTION

sub threshold micro pulse laser for DME for group 1 and intravitreal injection of Ranibizumab for group 2

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* DME with BCVA\<0.5 decimal Snellen acuity.
* Controlled blood glucose (HbA1c) \<6.5%.

Exclusion Criteria

* History of previous intraocular surgery,
* History of previous laser treatment,
* History of previous IV injection,
* Macular disease or ischemia,
* Proliferative diabetic retinopathy,
* Vitreoretinal traction,
* Interruption of external limiting membrane (ELM) or ellipsoid zone (EZ).
* Dense media opacity,
* Optic disc pathology
* History of strokes or ischaemic heart diseases.
* patients with (CST) \> 400 µm on OCT .

Eligible Sex

ALL

Accepts Healthy Volunteers

No